Insider buying last 90 days
No open-market insider purchases were filed for SIBN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every SIBN insider filing, plotted on the chart in Gekko.Open SIBN in Gekko
NASDAQ: SIBN
SI-BONE (SIBN) Stock Analysis & Forecast
Oct 12 close
$20.10+0.73 (+3.8%)
Gekko Brief
AI summaryOct 12 closeThis week's news on SI-BONE consists mainly of insider sales, with director Jeffrey Dunn selling $369,400 in stock on October 1, 2026 under a pre-arranged trading plan while also acquiring shares through stock options, and COO & CFO Anshul Maheshwari selling approximately $94,078 in early October tied to tax withholding and a 10b5-1 plan. SVP Michael Pisetsky also sold $56,918 in stock to cover tax obligations from restricted stock unit vesting. These filings describe routine insider transactions rather than a company-driven event.
SIBN closed at $20.10, up 3.8%, and sits above both its 50-day average of $18.86 and 200-day average of $16.32, with the 50-day above the 200-day. The stock's one-month return stands at 9.4%, its three-month return at 18.9%, and its one-year return at 27.9%, with the 52-week range spanning $11.48 to $21.89. The GekkoIndex reads 51.5, placing it in the Neutral zone. Gekko Fair Value is set at $28.11, leaving price 28.5% below that level.
SI-BONE's next earnings date falls on 9 November 2026, 28 days away, after the close, which lands inside a typical 20-trading-day holding window; the prior quarter saw an EPS beat with a 3.8% reaction. Seasonality over the next 20 trading days has averaged a 5.3% gain across 5 years, rising in 4 of them. No insider, Congress or unusual options activity appears within their respective windows, and one trailblazer holder is noted. Consensus among 7 firms stands at a buy rating with a target of $25.22.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
SI-BONE price vs fair value
Close $20.10200-day averageGekko Fair Value $28.11
SI-BONE quick facts
- Market cap
- $891.4M
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.34
- Revenue, TTM
- $213.6M
- Profit margin
- -6.8%
- Dividend yield
- —
- Beta
- 0.66
- Volume
- 552,747 avg 590,161
- 1-year return
- +27.9%
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±8.8%
- 50-day average
- $18.86
- 200-day average
- $16.32
- Next earnings
- Nov 9 after close
- Shares outstanding
- 44.82M
SI-BONE swing-trade checklist
SI-BONE scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $20.10 is above the 50-day ($18.86) and 200-day ($16.32) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
51.5, Neutral
Reading 51.5 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
28.5% below
Price is 28.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Nov 9, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.3% on average
From this point in the calendar, the next 20 trading days averaged +5.3% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
SI-BONE stock chart and price history
SI-BONE closed at $20.10 on Oct 12, 2026, +27.9% over the past year, inside a 52-week range of $11.48 to $21.89.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +9.4%
- 3 months
- +18.9%
- 6 months
- +43.6%
- 1 year
- +27.9%
The full SIBN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SIBN in Gekko
Follow SI-BONE through every session
Put SIBN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SIBN in GekkoFree for 7 days. No credit card required.
About SI-BONE
SI-BONE designs and sells implant systems used to treat joint and bone problems in the sacropelvic area, with patients reached through hospitals and surgical practices in the United States and other countries. Its main product, iFuse, is a minimally invasive implant used for conditions such as sacroiliac joint dysfunction, degeneration of that joint, deformities of the adult spine, and fractures of the pelvic ring. The company has built on this with iFuse-3D, a titanium version that keeps the original triangular shape but adds a 3D-printed porous surface and openings in the implant, and iFuse-TORQ, a line of threaded, 3D-printed implants made for pelvic fracture repair and joint fusion procedures done with minimal invasion.
To bring these products to market, SI-BONE relies mainly on its own sales staff, supported by outside distributors who extend its reach further.
The company was founded in 2008 and is headquartered in Santa Clara, California. Its shares trade on the NASDAQ under the ticker SIBN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- si-bone.com
SI-BONE GekkoIndex: the smart money zone
SI-BONE’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.5, in the Neutral zone, down 2.7 points over five sessions.
51.5Neutral
Down 2.7 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | +0.1% | +3.2% | ||
| Accumulation | 257 | +0.4% | +1.7% | ||
| Neutral (current zone) | 346 | +0.1% | +0.1% | ||
| Distribution | 37 | +0.3% | −3.3% | ||
| Selling | 4 | Too few readings yet | |||
Average SIBN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the SIBN price, zone by zone.Track SIBN in Gekko
Is SI-BONE stock overvalued? Gekko Fair Value
SI-BONE trades 28.5% below Gekko Fair Value of $28.11, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what SI-BONE shares are worth, recalculated every trading day.
$28.11
Gekko Fair Value, Oct 10, 2026
28.5% Undervalued
At the end of Aug 2026 the price was 34.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open SIBN in Gekko
SI-BONE insider and Congress trading
No open-market insider purchases were filed for SI-BONE, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SIBN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SIBN, plotted on the chart in Gekko.Open SIBN in Gekko
Buybacks
SI-BONE has been buying back its own shares.
- Bought back, year ended Dec 31, 2018
- $73K
- As a share of market cap
- 0.01%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds SIBN.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
SI-BONE earnings: next date and track record
SI-BONE reports on Nov 9, 2026, after the close (28 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 9, 2026
Expected after the close, 28 days away
- EPS estimate
- −$0.13
- Revenue estimate
- $55.32M
8 of 8reports beat the EPS estimate
±10%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 3, 2026 AI summary
- What they said
- SI-BONE reported Q2 2026 worldwide revenue of $56M and U.S. revenue of $53.2M, both growing approximately 15% YoY. U.S. procedure volume increased 9% sequentially, the strongest Q2 sequential gain in years. Adjusted EBITDA improved 178% YoY as revenue grew nearly twice as fast as operating expenses. International revenue grew 26% to $2.8M. The company submitted a 510(k) for its third breakthrough-designated device targeting complex spine procedures.
- Guidance
- Management expects a strong finish to 2026, with a phased commercial launch of the new spine product potentially beginning in October 2026. 2027 outlook is positive, driven by new product adoption, improved territory productivity, and favorable reimbursement changes supporting broader utilization.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | −$0.09 est −$0.15 | $56.01M est $55.34M | +3.8% |
| May 11, 2026 | −$0.10 est −$0.15 | $52.59M est $51.16M | +13.3% |
| Feb 23, 2026 | −$0.04 est −$0.13 | $56.35M est $55.40M | −1.2% |
| Nov 10, 2025 | −$0.11 est −$0.16 | $48.66M est $56.26M | +15.5% |
| Aug 4, 2025 | −$0.14 est −$0.18 | $48.63M est $46.67M | −8.0% |
| May 5, 2025 | −$0.15 est −$0.24 | $47.29M est $46.71M | +17.6% |
| Feb 24, 2025 | −$0.11 est −$0.13 | $49.00M est $48.14M | +3.4% |
| Nov 12, 2024 | −$0.16 est −$0.24 | $40.34M est $46.89M | −17.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
SI-BONE stock forecast and analyst price targets
Analysts’ average 12-month price target for SI-BONE is $25.22, +25.5% from the last close, from 7 firms rating the stock in the last 90 days.
$25.22consensus 12-month target, +25.5% from the last close
Now $20.10Avg $25.22
Low $20High $27
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 29 | Canaccord Genuity | $27 | +34.3% |
| Sep 14 | Canaccord Genuity | $27 | +34.3% |
| Aug 4 | Bank of America Securities | — | — |
| Aug 4 | Truist Financial | $23 | +14.4% |
| Aug 4 | Piper Sandler | $25 | +24.4% |
+0.1%average 20-day move after past Neutral readings
+5.3%average move over the next 20 trading days in the last 5 years
±3.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
SI-BONE seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, SI-BONE averaged +5.3% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.1% | 2 of 5 |
| Next 10 trading days | −0.8% | 2 of 5 |
| Next 15 trading days | +2.7% | 4 of 5 |
| Next 20 trading days | +5.3% | 4 of 5 |
| Next 30 trading days | −3.4% | 1 of 5 |
For scale, SIBN’s typical 20-trading-day move in either direction is about 8.8%.
SI-BONE market cap and key statistics
SI-BONE’s market cap is $891.4M and revenue of $213.6M over the last twelve months.
Valuation
- Market cap
- $891.4M
- EPS, TTM
- −$0.34
- Gekko Fair Value
- $28.11
Trading
- Volume
- 552,747
- Avg volume, 20 days
- 590,161
- 52-week high
- $21.89
- 52-week low
- $11.48
- Shares outstanding
- 44.82M
Financials
- Revenue, TTM
- $213.6M
- Profit margin
- -6.8%
- Return on equity
- -8.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.66
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±8.8%
SI-BONE stock news this week
Coverage of SI-BONE this week reads neutral: 2 positive, 12 neutral and 1 negative headlines.
- Si-Bone director Jeffrey Dunn sells $369,400 in stock By Investing.comInvesting.com Canada, Oct 11
- Si-Bone COO & CFO Anshul Maheshwari sells $94,078 in company stockInvesting.com, Oct 11
- Form 4 Si-Bone Inc For: 11 October By Investing.comInvesting.com South Africa, Oct 11
- Si-Bone COO & CFO Anshul Maheshwari sells $94,078 in company stock By Investing.comInvesting.com South Africa, Oct 11
- Form 4 Si-Bone Inc For: 6 October By Investing.comInvesting.com Nigeria, Oct 8
- Si-Bone SVP Michael Pisetsky sells $56,918 in stockInvesting.com, Oct 7
SI-BONE peers
SI-BONE’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
SI-BONE stock FAQ
What is SI-BONE’s market cap?
SI-BONE’s market cap is $891.4M at the Oct 12, 2026 close of $20.10, with 44.82M shares outstanding.
What is the SI-BONE stock forecast?
The consensus analyst 12-month price target for SI-BONE is $25.22, +25.5% from the last close. Of the 7 firms that rated the stock in the last 90 days, 7 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is SI-BONE stock overvalued or undervalued?
On Gekko’s estimate SI-BONE is undervalued: the Oct 12, 2026 close of $20.10 is 28.5% below Gekko Fair Value of $28.11. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does SI-BONE report earnings next?
SI-BONE is expected to report on Nov 9, 2026, after the market closes (28 days away). Analysts expect earnings of −$0.13 per share on revenue of $55.32M. SI-BONE beat the earnings estimate in 8 of its last 8 reports, moving 10% on average across the report.
What is SI-BONE’s 52-week high and low?
SI-BONE’s 52-week high is $21.89 and its 52-week low is $11.48; it closed at $20.10 on Oct 12, 2026, +27.9% over the past year. Over the last five years the shares peaked at $29.51 on Jun 14, 2023.
Is SI-BONE stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See SI-BONE the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.